KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Current Liabilities (2018 - 2025)

Esperion Therapeutics' Total Current Liabilities history spans 8 years, with the latest figure at $300.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 22.16% year-over-year to $300.8 million; the TTM value through Dec 2025 reached $300.8 million, up 22.16%, while the annual FY2025 figure was $300.8 million, 22.16% up from the prior year.
  • Total Current Liabilities reached $300.8 million in Q4 2025 per ESPR's latest filing, down from $359.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $359.0 million in Q3 2025 to a low of $73.4 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $157.3 million, with a median of $122.4 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: dropped 22.02% in 2021, then skyrocketed 116.45% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $73.4 million in 2021, then grew by 25.84% to $92.3 million in 2022, then skyrocketed by 69.24% to $156.2 million in 2023, then soared by 57.62% to $246.2 million in 2024, then increased by 22.16% to $300.8 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Total Current Liabilities are $300.8 million (Q4 2025), $359.0 million (Q3 2025), and $298.8 million (Q2 2025).